Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093251 | 0.95 | SIGMAR1 (0.71) | SIGMAR1LTA4HGRIN2BSLC6A3HRH3 | |
| SCHEMBL2093478 | 0.94 | SIGMAR1 (0.73) | SIGMAR1LTA4HGRIN2BSLC6A3HRH3 | |
| SCHEMBL2097395 | 0.94 | SIGMAR1 (0.73) | SIGMAR1LTA4HGRIN2BSLC6A3HRH3 | |
| SCHEMBL42714 | 0.93 | SIGMAR1 (0.75) | SIGMAR1LTA4HPOLBCCR3 | |
| SCHEMBL2779057 | 0.90 | SLC6A3 (0.70) | SIGMAR1LTA4HSLC6A3HRH3CCR3 | |
| SCHEMBL2096501 | 0.88 | SIGMAR1 (0.69) | SIGMAR1GRIN2BPOLBCCR3 | |
| SCHEMBL2089113 | 0.87 | SIGMAR1 (0.72) | SIGMAR1GRIN2BPOLBCCR3 | |
| SCHEMBL2099250 | 0.87 | SIGMAR1 (0.72) | SIGMAR1GRIN2BPOLBCCR3 | |
| SCHEMBL5302082 | 0.84 | LTA4H (0.86) | SIGMAR1LTA4HGRIN2BPOLBSLC6A3 | |
| SCHEMBL83687 | 0.83 | SIGMAR1 (0.86) | SIGMAR1LTA4HGRIN2BPOLBSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | SIGMAR1 161/4885LTA4H 3093/4885GRIN2B 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.